Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Veracyte is poised for continued success and growth based on their innovative technologies, strong partnerships, and expanding testing options for multiple types of cancer. Veracyte's partnership and utilization of GRID technology has strengthened their position in the cancer diagnostics market, particularly with their successful Afirma and Decipher tests. Their financial stability, lack of debt, and focus on organic growth leave them well-equipped to navigate potential challenges. With the launch of their new platform, TrueMRD, and ongoing legal battles with competitors, Veracyte is positioned for continued success.

Bears say

Veracyte is a company with strong potential for long-term growth, thanks to its expanding portfolio of genomic diagnostics tests that aim to improve cancer diagnosis and treatment. However, Veracyte is not without risks, as its market is highly competitive and subject to policy changes, potentially affecting reimbursement and pricing. Additionally, the company's reliance on guideline recognition and positive clinical data for continued growth could prove challenging in the future. While Veracyte currently has strong financials and margins, there is a risk of margin compression if the company aggressively expands its market reach and invests in new product launches.

Veracyte (VCYT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 9 analysts, Veracyte (VCYT) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.